Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: J Thorac Cardiovasc Surg. 2019 Nov 13;160(1):261–271.e1. doi: 10.1016/j.jtcvs.2019.10.102

FIGURE 3.

FIGURE 3.

A, Kaplan-Meier unadjusted survival curves for patients with pathologic N1 and N2 non-small cell lung cancer stratified by use of National Comprehensive Cancer Network guideline-concordant adjuvant therapy, defined as chemotherapy for pathologic N1 disease and chemotherapy with or without radiation for pathologic N2 disease, versus guideline-discordant therapy (other therapy or omission of concordant adjuvant therapy). B, Kaplan-Meier unadjusted survival curves for patients with pathologic N2 non-small cell lung cancer, stratified by use of guideline-concordant adjuvant therapy (defined as chemoradiation or chemotherapy only) versus guideline-discordant adjuvant therapy (radiation therapy [RT] only or omission of adjuvant therapy [none]).